Inventor · disambiguated record
Paride Grisenti
Also filed as: GRISENTI PARIDE
16 granted patents·6 pending applications·123 citations·filing 1995–2024
91Inventor score
Top patents by PatentIndex Score
22 records- 0185US6147213ADiastereomerically pure 3-oxo and 3-thioxo-4-aza-androstan derivatives and the use thereof as antiandrogensPOLICHEM SA·Filed 1995·Granted Nov 14, 2000·64 cites·3 claims
- 0280US10961257B2Polymorphic mixture of rifaximin and its use for the preparation of solid formulationsAMRI ITALY S R L·Filed 2019·Granted Mar 30, 2021·2 cites·11 claims
- 0378US6395901B1Process for the preparation of alkyl mercapto methyl ergoline derivativesPOLI IND CHIMICA SPA·Filed 2000·Granted May 28, 2002·13 cites·29 claims
- 0473US2023234966A1Polymorphic mixture of rifaximin and its use for the preparation of solid formulationsCURIA IP HOLDINGS LLC·Filed 2023·Application pending·0 cites
- 0572US7727751B2Method for the preparation of mycophenolate mofetil by enzyme tranesterificationPOLI IND CHIMICA SPA·Filed 2005·Granted Jun 1, 2010·4 cites·24 claims
- 0671US9169269B2Water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrinsMANGIA ALBERTO·Filed 2011·Granted Oct 27, 2015·7 cites·18 claims
- 0769US5817803AProcess for preparing neuromuscular blocking agents and intermediates useful thereforPOLI IND CHIMICA SPA·Filed 1996·Granted Oct 6, 1998·17 cites·49 claims
- 0868US2022048926A1Polymorphic mixture of rifaximin and its use for the preparation of solid formulationsCURIA IP HOLDINGS LLC·Filed 2021·Application pending·0 cites
- 0966US11739099B2Polymorphic mixture of Rifaximin and its use for the preparation of solid formulationsCURIA IP HOLDINGS LLC·Filed 2021·Granted Aug 29, 2023·0 cites·14 claims
- 1066US10745415B2Polymorphic mixture of Rifaximin and its use for the preparation of solid formulationsEUTICALS SPA·Filed 2019·Granted Aug 18, 2020·0 cites·16 claims
- 1162US5808051AProcess for preparing neuromuscular blocking agents and intermediates useful thereforPOLI IND CHIMICA SPA·Filed 1997·Granted Sep 15, 1998·11 cites·18 claims
- 1261US2024398908A1Stable gel formulations for the treatment of acne vulgarisBIOSEUTICA B V·Filed 2024·Application pending·0 cites
- 1359US2024148837A1Ovotransferrins for use in the treatment of iron deficiency anaemiaBIOSEUTICA B V·Filed 2022·Application pending·0 cites
- 1454US10556915B2Polymorphic mixture of Rifaximin and its use for the preparation of solid formulationsEUTICALS SPA·Filed 2015·Granted Feb 11, 2020·0 cites·4 claims
- 1551US2024317791A1A process for the production of amcipatricin diascorbate and the use of the same for the treatment of invasive fungal infections resistant to traditional antifungal agentsBIOSEUTICA B V·Filed 2022·Application pending·0 cites
- 1647US6090957AProcess for preparing neuromuscular blocking agents and intermediates useful thereforPOLI IND CHIMICA SPA·Filed 1998·Granted Jul 18, 2000·5 cites·12 claims
- 1745US2023174575A1A new process of purification of proteins from hen egg white and the use of the same as antiviral agent against sars-cov-2BIOSEUTICA B V·Filed 2021·Application pending·0 cites
- 1840US9630923B2Biocatalyzed synthesis of the optically pure (R) and (S) 3-methyl-1,2,3,4-tetrahydroquinoline and their use as chiral synthons for the preparation of the antithrombic (21R)- and (21S)-argatrobanEUTICALS SPA·Filed 2016·Granted Apr 25, 2017·0 cites·20 claims
- 1940US7667056B2Process and new intermediates for the preparation of steroids with a progestogen activityPOLI IND CHIMICA SPA·Filed 2003·Granted Feb 23, 2010·0 cites·30 claims
- 2038US9765082B2Crystalline form of tiotropium bromide with lactoseEUTICALS SPA·Filed 2016·Granted Sep 19, 2017·0 cites·21 claims
- 2131US10144756B2Stable solid forms of regadenosonEUTICALS SPA·Filed 2015·Granted Dec 4, 2018·0 cites·23 claims
- 2230US8778636B2Chemo-enzymatic approach to the synthesis of pimecrolimusGRISENTI PARIDE·Filed 2010·Granted Jul 15, 2014·0 cites·35 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →